encodeslife Competitors

Genedata transforms biopharma data into intelligence. Our innovative software solutions combine deep science, technology, and AI domain knowledge. Leading biopharma organizations and cutting-edge biotechs partner with Genedata to digitalize and automate complex data workflows. Our advanced analytics and embedded AI enable data-driven decisions. From early discovery through development to the clinic, Genedata solutions drive innovation and maximize ROI being trusted by customers worldwide for more than 25 years. Genedata is proud to be part of Danaher, a global life sciences and diagnostics innovator committed to accelerating the power of science and technology to improve human health. As part of Danaher, Genedata is connected to a uniquely broad ecosystem of expertise, technologies, and capabilities. Together, we partner closely with customers to solve their toughest challenges with greater speed and certainty. Powered by the rigor of the Danaher Business System and a culture of continuous improvement, we make time a competitive advantage for our customers and help unlock the transformative potential of science and technology to improve billions of lives every day.

About Genomic Health Genomic Health, Inc. (NASDAQ: GHDX) is the world's leading provider of genomic-based diagnostic tests that help optimize cancer care by addressing the overtreatment of the disease, one of the greatest issues in healthcare today. With its Oncotype IQ® Genomic Intelligence Platform, the company is applying its world-class scientific and commercial expertise and infrastructure to lead the translation of clinical and genomic big data into actionable results for treatment planning throughout the cancer patient journey, from diagnosis to treatment selection and monitoring. The Oncotype IQ portfolio of genomic tests and services currently consists of the company's flagship line of Oncotype DX gene expression tests that have been used to guide treatment decisions for more than 750,000 cancer patients worldwide. Genomic Health is expanding its test portfolio to include additional liquid- and tissue-based tests, including the recently launched Oncotype SEQ® Liquid Select™ test. The company is based in Redwood City, California, with international headquarters in Geneva, Switzerland. For more information, please visit, www.GenomicHealth.com and follow the company on Twitter: @GenomicHealth, Facebook, YouTube and LinkedIn. About Oncotype DX® The Oncotype DX® portfolio of breast, colon and prostate cancer tests applies advanced genomic science to reveal the unique biology of a tumor in order to optimize cancer treatment decisions. The company's flagship product, the Oncotype DX Breast Recurrence Score®, has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer. Additionally, the Oncotype DX Breast DCIS Score™ predicts the likelihood of recurrence in a pre-invasive form of breast cancer called DCIS. In prostate cancer, the Oncotype DX Genomic Prostate Score™ predicts disease aggressiveness and further clarifies the current and future risk of the cancer prior to treatment intervention. With more than 750,000 patients tested in more than 90 countries, the Oncotype DX tests have redefined personalized medicine by making genomics a critical part of cancer diagnosis and treatment. To learn more about Oncotype DX tests, visit www.OncotypeIQ.com, www.MyBreastCancerTreatment.org or www.MyProstateCancerTreatment.org.

Genomic Life is committed to improving the health and well-being of individuals, employees, and populations through our genomics navigation services. We collaborate with employers, third-party administrators, public institutions, and large groups to provide essential genomic screenings and personalized cancer navigation. Our goal is to ensure timely access to genomic-based solutions and expert cancer care resources, effectively reducing the burden of genetic diseases and cancer to ultimately enhance outcomes. Genomic Life's personalized navigation approach make it possible for everyone in your population, and their care team, to take more control of the health care journey by helping to understand your risk for a disease before it occurs or further progresses. If an individual within your population receives a cancer diagnosis, they are not alone. They have access to an ultrapersonalized cancer support program provided by Genomic Life. Each individual receives a dedicated oncology navigator who offers timely access to genomic-based solutions and expert cancer care resources throughout every situation and stage, thus alleviating the burden of cancer. At Genomic Life, we prioritize individual navigation, firmly believing that everyone deserves to live their best life. As pioneers in evidence-based employee benefits, we have assembled a team of experts in genomics, cancer navigation, technology, and design to provide easy access to ongoing guidance, genetic screenings, and personalized cancer navigation. If you are seeking to optimize the health of your employees and members, let's collaborate to harness the power of genetic screenings and cancer navigation for your organization or community. Reach out to us today to initiate the conversation! Contact us for more information at 844-694-3666